|
1
|
Stupp R, Mason WP, Van den Bent MJ, Weller
M, Fisher B, Taphoorn MJ, Belanger K, Brandes AA, Marosi C, Bogdahn
U, et al European Organisation for Research and Treatment of Cancer
Brain Tumor and Radiotherapy Groups, ; National Cancer Institute of
Canada Clinical Trials Group, : Radiotherapy plus concomitant and
adjuvant temozolomide for glioblastoma. N Engl J Med. 352:987–996.
2005. View Article : Google Scholar : PubMed/NCBI
|
|
2
|
Wen PY and Kesari S: Malignant gliomas in
adults. N Engl J Med. 359:492–507. 2008. View Article : Google Scholar : PubMed/NCBI
|
|
3
|
Walecki J, Tarasów E, Kubas B, Czemicki Z,
Lewko J, Podgórski J, Sokól M and Grieb P: Hydrogen-1 MR
spectroscopy of the peritumoral zone in patients with cerebral
glioma: Assessment of the value of the method. Acad Radiol.
10:145–153. 2003. View Article : Google Scholar : PubMed/NCBI
|
|
4
|
Stupp R, Hegi ME, Mason WP, Van den Bent
MJ, Taphoorn MJ, Janzer RC, Ludwin SK, Allgeier A, Fisher B,
Belanger K, et al European Organisation for Research and Treatment
of Cancer Brain Tumour and Radiation Oncology Groups, ; National
Cancer Institute of Canada Clinical Trials Group, : Effects of
radiotherapy with concomitant and adjuvant temozolomide versus
radiotherapy alone on survival in glioblastoma in a randomised
phase III study: 5-year analysis of the EORTC-NCIC trial. Lancet
Oncol. 10:459–466. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
5
|
Stupp R and Hegi ME: Brain cancer in 2012:
Molecular characterization leads the way. Nat Rev Clin Oncol.
10:69–70. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
6
|
Knizhnik AV, Roos WP, Nikolova T, Quiros
S, Tomaszowski KH, Christmann M and Kaina B: Survival and death
strategies in glioma cells: Autophagy, senescence and apoptosis
triggered by a single type of temozolomide-induced DNA damage. PLoS
One. 8:e556652013. View Article : Google Scholar : PubMed/NCBI
|
|
7
|
Xiao S, Yang Z, Qiu X, Lv R, Liu J, Wu M,
Liao Y and Liu Q: miR-29c contribute to glioma cells temozolomide
sensitivity by targeting O6-methylguanine-DNA
methyltransferases indirectely. Oncotarget. 7:50229–50238; Epub
ahead of print. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
8
|
Hermisson M, Klumpp A, Wick W, Wischhusen
J, Nagel G, Roos W, Kaina B and Weller M:
O6-methylguanine DNA methyltransferase and p53 status
predict temozolomide sensitivity in human malignant glioma cells. J
Neurochem. 96:766–776. 2006. View Article : Google Scholar : PubMed/NCBI
|
|
9
|
Zhang K, Wang XQ, Zhou B and Zhang L: The
prognostic value of MGMT promoter methylation in glioblastoma
multiforme: A meta-analysis. Fam Cancer. 12:449–458. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
10
|
Wang H, Feng W, Lu Y, Li H, Xiang W, Chen
Z, He M, Zhao L, Sun X, Lei B, et al: Expression of dynein,
cytoplasmic 2, heavy chain 1 (DHC2) associated with glioblastoma
cell resistance to temozolomide. Sci Rep. 6:289482016. View Article : Google Scholar : PubMed/NCBI
|
|
11
|
Bartel DP: MicroRNAs: Genomics,
biogenesis, mechanism, and function. Cell. 116:281–297. 2004.
View Article : Google Scholar : PubMed/NCBI
|
|
12
|
Bartel DP: MicroRNAs: Target recognition
and regulatory functions. Cell. 136:215–233. 2009. View Article : Google Scholar : PubMed/NCBI
|
|
13
|
Shukla GC, Singh J and Barik S: MicroRNAs:
Processing, maturation, target recognition and regulatory
functions. Mol Cell Pharmacol. 3:83–92. 2011.PubMed/NCBI
|
|
14
|
Hummel R, Hussey DJ and Haier J:
MicroRNAs: Predictors and modifiers of chemo- and radiotherapy in
different tumour types. Eur J Cancer. 46:298–311. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
15
|
Wei J, Qi X, Zhan Q, Zhou D, Yan Q, Wang
Y, Mo L, Wan Y, Xie D, Xie J, et al: miR-20a mediates
temozolomide-resistance in glioblastoma cells via negatively
regulating LRIG1 expression. Biomed Pharmacother. 71:112–118. 2015.
View Article : Google Scholar : PubMed/NCBI
|
|
16
|
Ujifuku K, Mitsutake N, Takakura S,
Matsuse M, Saenko V, Suzuki K, Hayashi K, Matsuo T, Kamada K,
Nagata I, et al: miR-195, miR-455-3p and miR-10a(*) are implicated
in acquired temozolomide resistance in glioblastoma multiforme
cells. Cancer Lett. 296:241–248. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
17
|
Wang J, Sai K, Chen FR and Chen ZP:
miR-181b modulates glioma cell sensitivity to temozolomide by
targeting MEK1. Cancer Chemother Pharmacol. 72:147–158. 2013.
View Article : Google Scholar : PubMed/NCBI
|
|
18
|
Li Y, Wang Y, Yu L, Sun C, Cheng D, Yu S,
Wang Q, Yan Y, Kang C, Jin S, et al: miR-146b-5p inhibits glioma
migration and invasion by targeting MMP16. Cancer Lett.
339:260–269. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
19
|
van Thuijl HF, Scheinin I, Sie D, Alentorn
A, van Essen HF, Cordes M, Fleischeuer R, Gijtenbeek AM, Beute G,
Van den Brink WA, et al: Spatial and temporal evolution of distal
10q deletion, a prognostically unfavorable event in diffuse
low-grade gliomas. Genome Biol. 15:4712014. View Article : Google Scholar : PubMed/NCBI
|
|
20
|
Weller M, Weber RG, Willscher E, Riehmer
V, Hentschel B, Kreuz M, Felsberg J, Beyer U, Löffler-Wirth H,
Kaulich K, et al: Molecular classification of diffuse cerebral WHO
grade II/III gliomas using genome- and transcriptome-wide profiling
improves stratification of prognostically distinct patient groups.
Acta Neuropathol. 129:679–693. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
21
|
Yang W, Yu H, Shen Y, Liu Y, Yang Z and
Sun T: MiR-146b-5p overexpression attenuates stemness and
radioresistance of glioma stem cells by targeting
HuR/lincRNA-p21/β-catenin pathway. Oncotarget. 7:41505–41526. 2016.
View Article : Google Scholar : PubMed/NCBI
|
|
22
|
Liu H, Tamashiro S, Baritaki S, Penichet
M, Yu Y, Chen H, Berenson J and Bonavida B: TRAF6 activation in
multiple myeloma: A potential therapeutic target. Clin Lymphoma
Myeloma Leuk. 12:155–163. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
23
|
Inoue J, Gohda J and Akiyama T:
Characteristics and biological functions of TRAF6. Adv Exp Med
Biol. 597:72–79. 2007. View Article : Google Scholar : PubMed/NCBI
|
|
24
|
Chen ZJ: Ubiquitination in signaling to
and activation of IKK. Immunol Rev. 246:95–106. 2012. View Article : Google Scholar : PubMed/NCBI
|
|
25
|
Lin Y, Qiu Y, Xu C, Liu Q, Peng B,
Kaufmann GF, Chen X, Lan B, Wei C, Lu D, et al: Functional role of
asparaginyl endopeptidase ubiquitination by TRAF6 in tumor invasion
and metastasis. J Natl Cancer Inst. 106:dju0122014. View Article : Google Scholar : PubMed/NCBI
|
|
26
|
Starczynowski DT, Lockwood WW, Deléhouzée
S, Chari R, Wegrzyn J, Fuller M, Tsao MS, Lam S, Gazdar AF, Lam WL,
et al: TRAF6 is an amplified oncogene bridging the RAS and NF-κB
pathways in human lung cancer. J Clin Invest. 121:4095–4105. 2011.
View Article : Google Scholar : PubMed/NCBI
|
|
27
|
Sun H, Li X, Fan L, Wu G, Li M and Fang J:
TRAF6 is upregulated in colon cancer and promotes proliferation of
colon cancer cells. Int J Biochem Cell Biol. 53:195–201. 2014.
View Article : Google Scholar : PubMed/NCBI
|
|
28
|
Liu J, Xu J, Li H, Sun C, Yu L, Li Y, Shi
C, Zhou X, Bian X, Ping Y, et al: miR-146b-5p functions as a tumor
suppressor by targeting TRAF6 and predicts the prognosis of human
gliomas. Oncotarget. 6:29129–29142. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
29
|
Yi GZ, Liu YW, Xiang W, Wang H, Chen ZY,
Xie SD and Qi ST: Akt and β-catenin contribute to TMZ resistance
and EMT of MGMT negative malignant glioma cell line. J Neurol Sci.
367:101–106. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
30
|
Kim SH, Joshi K, Ezhilarasan R, Myers TR,
Siu J, Gu C, Nakano-Okuno M, Taylor D, Minata M, Sulman EP, et al:
EZH2 protects glioma stem cells from radiation-induced cell death
in a MELK/FOXM1-dependent manner. Stem Cell Rep. 4:226–238. 2015.
View Article : Google Scholar
|
|
31
|
Shi L, Fei X, Wang Z and You Y: PI3K
inhibitor combined with miR-125b inhibitor sensitize TMZ-induced
anti-glioma stem cancer effects through inactivation of
Wnt/β-catenin signaling pathway. In Vitro Cell Dev Biol Anim.
51:1047–1055. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
32
|
Fukushima T, Takeshima H and Kataoka H:
Anti-glioma therapy with temozolomide and status of the DNA-repair
gene MGMT. Anticancer Res. 29:4845–4854. 2009.PubMed/NCBI
|
|
33
|
Yan Y, Xu Z, Dai S, Qian L, Sun L and Gong
Z: Targeting autophagy to sensitive glioma to temozolomide
treatment. J Exp Clin Cancer Res. 35:232016. View Article : Google Scholar : PubMed/NCBI
|
|
34
|
Sun YC, Wang J, Guo CC, Sai K, Wang J,
Chen FR, Yang QY, Chen YS, Wang J, To TS, et al: MiR-181b
sensitizes glioma cells to teniposide by targeting MDM2. BMC
Cancer. 14:6112014. View Article : Google Scholar : PubMed/NCBI
|
|
35
|
Comincini S, Allavena G, Palumbo S, Morini
M, Durando F, Angeletti F, Pirtoli L and Miracco C: microRNA-17
regulates the expression of ATG7 and modulates the autophagy
process, improving the sensitivity to temozolomide and low-dose
ionizing radiation treatments in human glioblastoma cells. Cancer
Biol Ther. 14:574–586. 2013. View Article : Google Scholar : PubMed/NCBI
|
|
36
|
Chen L, Zhang J, Han L, Zhang A, Zhang C,
Zheng Y, Jiang T, Pu P, Jiang C and Kang C: Downregulation of
miR-221/222 sensitizes glioma cells to temozolomide by regulating
apoptosis independently of p53 status. Oncol Rep. 27:854–860.
2012.PubMed/NCBI
|
|
37
|
Bo LJ, Wei B, Li ZH, Wang ZF, Gao Z and
Miao Z: Bioinformatics analysis of miRNA expression profile between
primary and recurrent glioblastoma. Eur Rev Med Pharmacol Sci.
19:3579–3586. 2015.PubMed/NCBI
|
|
38
|
Katakowski M, Zheng X, Jiang F, Rogers T,
Szalad A and Chopp M: MiR-146b-5p suppresses EGFR expression and
reduces in vitro migration and invasion of glioma. Cancer Invest.
28:1024–1030. 2010. View Article : Google Scholar : PubMed/NCBI
|
|
39
|
Starczynowski DT, Kuchenbauer F,
Argiropoulos B, Sung S, Morin R, Muranyi A, Hirst M, Hogge D, Marra
M, Wells RA, et al: Identification of miR-145 and miR-146a as
mediators of the 5q- syndrome phenotype. Nat Med. 16:49–58. 2010.
View Article : Google Scholar : PubMed/NCBI
|
|
40
|
Meng Q, Zheng M, Liu H, Song C, Zhang W,
Yan J, Qin L and Liu X: TRAF6 regulates proliferation, apoptosis,
and invasion of osteosarcoma cell. Mol Cell Biochem. 371:177–186.
2012. View Article : Google Scholar : PubMed/NCBI
|
|
41
|
Han F, Zhang L, Qiu W and Yi X: TRAF6
promotes the invasion and metastasis and predicts a poor prognosis
in gastric cancer. Pathol Res Pract. 212:31–37. 2016. View Article : Google Scholar : PubMed/NCBI
|
|
42
|
Caporali S, Levati L, Graziani G, Muzi A,
Atzori MG, Bonmassar E, Palmieri G, Ascierto PA and D'Atri S: NF-κB
is activated in response to temozolomide in an AKT-dependent manner
and confers protection against the growth suppressive effect of the
drug. J Transl Med. 10:2522012. View Article : Google Scholar : PubMed/NCBI
|
|
43
|
Liu JF, Tsao YT and Hou CH:
Fractalkine/CX3CL1 induced intercellular adhesion
molecule-1-dependent tumor metastasis through the
CX3CR1/PI3K/Akt/NF-κB pathway in human osteosarcoma. Oncotarget.
Aug 12–2016.(Epub ahead of print). doi:
10.18632/oncotarget.11250.
|
|
44
|
Zou W, Ma X, Hua W, Chen B and Cai G:
Caveolin-1 mediates chemoresistance in cisplatin-resistant ovarian
cancer cells by targeting apoptosis through the Notch-1/Akt/NF-κB
pathway. Oncol Rep. 34:3256–3263. 2015. View Article : Google Scholar : PubMed/NCBI
|
|
45
|
Barré B and Perkins ND: The Skp2 promoter
integrates signaling through the NF-kappaB, p53, and Akt/GSK3beta
pathways to regulate autophagy and apoptosis. Mol Cell. 38:524–538.
2010. View Article : Google Scholar : PubMed/NCBI
|
